Literature DB >> 17461450

Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases.

Ichiro Hirata1, Masahiro Hoshimoto, Osamu Saito, Masanobu Kayazawa, Takashi Nishikawa, Mitsuyuki Murano, Ken Toshina, Fang-Yu Wang, Ryoichi Matsuse.   

Abstract

AIM: To evaluate prospectively usefulness of fecal lactoferrin (Lf) and fecal hemoglobin (Hb) in the diagnosis of colorectal diseases.
METHODS: Fecal Lf and Hb were measured using ELISA in 872 patients before they underwent colorectal endoscopy.
RESULTS: Lf was positive in 18 (50%) of 36 patients with colorectal cancer, 25 (15.9%) of 157 with colorectal polyps, 29 (46.8%) of 62 with ulcerative colitis, and 25 (62.5%) of 40 (62.5%) with Crohn's disease. The Hb-positive rates were 50%, 12.1%, 41.9% and 32.5%, respectively. Of the 318 patients free of abnormalities by colorectal endoscopy, Lf was positive in 29 (9.1%) and Hb was positive in 15 (4.7%). Among patients with Crohn's disease, the Lf-positive rate was significantly higher than the Hb-positive rate. If either high Lf or Hb levels were considered positive, the positive rates rose to 61.1%, 51.6%, and 67.5% in the colorectal cancer group, ulcerative colitis group, and Crohn's disease group, respectively. If both high Lf and Hb levels were rated positive, the positive predictive values (PPV) were 21% for colorectal cancer, 33% for ulcerative colitis, and 17% for Crohn's disease, and PPV of high Hb level alone was 18%, 25% and 13%, respectively.
CONCLUSION: Fecal Lf and Hb were found useful in the detection of colorectal diseases, and the combination of the two measurements appears to increase the sensitivity and efficacy of diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461450      PMCID: PMC4146900          DOI: 10.3748/wjg.v13.i10.1569

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

Review 1.  Screening for colorectal cancer: current status in Japan.

Authors:  H Saito
Journal:  Dis Colon Rectum       Date:  2000-10       Impact factor: 4.585

2.  Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.

Authors:  J Kristinsson; K Nygaard; E Aadland; S Barstad; J Sauar; B Hofstad; N Stray; A Stallemo; B Haug; M Ugstad; H Tøn; P Fuglerud
Journal:  Digestion       Date:  2001       Impact factor: 3.216

3.  Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel.

Authors:  D A Ahlquist; J E Skoletsky; K A Boynton; J J Harrington; D W Mahoney; W E Pierceall; S N Thibodeau; A P Shuber
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

4.  Detecting colorectal cancer in stool with the use of multiple genetic targets.

Authors:  S M Dong; G Traverso; C Johnson; L Geng; R Favis; K Boynton; K Hibi; S N Goodman; M D'Allessio; P Paty; S R Hamilton; D Sidransky; F Barany; B Levin; A Shuber; K W Kinzler; B Vogelstein; J Jen
Journal:  J Natl Cancer Inst       Date:  2001-06-06       Impact factor: 13.506

5.  Cancer statistics, 2001.

Authors:  R T Greenlee; M B Hill-Harmon; T Murray; M Thun
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

6.  Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.

Authors:  J Tibble; G Sigthorsson; R Foster; R Sherwood; M Fagerhol; I Bjarnason
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

7.  High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial.

Authors:  G F Howarth; M H E Robinson; D Jenkins; J D Hardcastle; R F A Logan
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

8.  Fecal eosinophil granule-derived proteins reflect disease activity in inflammatory bowel disease.

Authors:  O Saitoh; K Kojima; K Sugi; R Matsuse; K Uchida; K Tabata; K Nakagawa; M Kayazawa; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

9.  Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation.

Authors:  Sunanda V Kane; William J Sandborn; Paul A Rufo; Anna Zholudev; James Boone; David Lyerly; Michael Camilleri; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

10.  Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.

Authors:  K Sugi; O Saitoh; I Hirata; K Katsu
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

View more
  14 in total

1.  Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.

Authors:  Ji-Gui Chen; Juan Cai; Huan-Lei Wu; Hua Xu; Yu-Xing Zhang; Chao Chen; Qian Wang; Jun Xu; Xiang-Lin Yuan
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

2.  Effect of Aqueous Extract of Phenolic Compounds Obtained from Red Wine in Experimental Model of Colitis in Mice.

Authors:  Vanessa Mateus; João Estarreja; Inês Silva; Fernando Gonçalves; Edite Teixeira-Lemos; Rui Pinto
Journal:  Curr Issues Mol Biol       Date:  2022-06-18       Impact factor: 2.976

3.  Lactoferrin Isolation Using Monolithic Column Coupled with Spectrometric or Micro-Amperometric Detector.

Authors:  Vojtech Adam; Ondrej Zitka; Petr Dolezal; Ladislav Zeman; Ales Horna; Jaromir Hubalek; Jan Sileny; Sona Krizkova; Libuse Trnkova; Rene Kizek
Journal:  Sensors (Basel)       Date:  2008-01-24       Impact factor: 3.576

4.  Usefulness of ascitic fluid lactoferrin levels in patients with liver cirrhosis.

Authors:  Sang Soo Lee; Hyun Ju Min; Ja Yun Choi; Hyun Chin Cho; Jin Joo Kim; Jae Min Lee; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae Hyo Kim; Jin Hyun Kim; Ok-Jae Lee
Journal:  BMC Gastroenterol       Date:  2016-10-13       Impact factor: 3.067

5.  Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study.

Authors:  Takayuki Yamamoto; Toshiaki Tanaka; Tadashi Yokoyama; Takahiro Shimoyama; Hiroki Ikeuchi; Motoi Uchino; Toshiaki Watanabe
Journal:  Therap Adv Gastroenterol       Date:  2016-11-25       Impact factor: 4.409

6.  Relating Stool Microbial Metabolite Levels, Inflammatory Markers and Dietary Behaviors to Screening Colonoscopy Findings in a Racially/Ethnically Diverse Patient Population.

Authors:  Kristina M Bridges; Francisco J Diaz; Zhiwen Wang; Ishfaq Ahmed; Debra K Sullivan; Shahid Umar; Daniel C Buckles; K Allen Greiner; Christina M Hester
Journal:  Genes (Basel)       Date:  2018-02-26       Impact factor: 4.096

7.  Hemin reduces inflammation associated with TNBS-induced colitis.

Authors:  Vanessa Mateus; João Rocha; Hélder Mota-Filipe; Bruno Sepodes; Rui Pinto
Journal:  Clin Exp Gastroenterol       Date:  2018-09-18

8.  Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis.

Authors:  Tobias Niedermaier; Yesilda Balavarca; Hermann Brenner
Journal:  Am J Gastroenterol       Date:  2020-01       Impact factor: 12.045

9.  Molecular mechanism of inhibitory effects of bovine lactoferrin on the growth of oral squamous cell carcinoma.

Authors:  Chanbora Chea; Mutsumi Miyauchi; Toshihiro Inubushi; Nurina Febriyanti Ayuningtyas; Ajiravudh Subarnbhesaj; Phuong Thao Nguyen; Madhu Shrestha; Sivmeng Haing; Kouji Ohta; Takashi Takata
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

Review 10.  Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis.

Authors:  Inês Silva; Rui Pinto; Vanessa Mateus
Journal:  J Clin Med       Date:  2019-10-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.